

For Immediate Release

TSX Exchange Symbol: RVX

Dr. Roger Newton, Co-discoverer of Lipitor®, Joins Resverlogix Board of Directors

Suite 202

279 Midpark Way SE

Calgary AB T2X 1M2

P 403.254.9252

F 403.256.8495

info@resverlogix.com

Calgary, AB May 14, 2007 – Resverlogix Corp. (“Resverlogix”) (TSX:RVX) is pleased to announce today that the Board of Directors has appointed Roger Newton, PhD, to the Board effective July 10, 2007.

“I am very pleased to be joining the Board of Directors of Resverlogix. It is a very exciting time for the NexVas™ Plaque Regression technology”, stated Dr. Newton. “We know that raising ApoA-I and functional HDL can regress atherosclerosis and this technology has the potential to be first in a new class of drugs for the treatment of cardiovascular disease due to atherosclerosis.”

Dr. Newton has worked 25 years in the pharmaceutical and life sciences industries. He is currently Senior Vice President of Pfizer Global Research and Development and Director, Esperion Therapeutics, a Pfizer Inc. Company. He was formerly Co-Founder, President and CEO of Esperion Therapeutics, Inc. (NASDAQ:ESPR), a biopharmaceutical company founded in July 1998 and located in Ann Arbor, MI. Esperion is dedicated to the discovery and development of pharmaceutical products for the treatment of cardiovascular diseases through the use of a new treatment approach called "HDL Therapy". Esperion was acquired by Pfizer in February 2004 for \$1.3 billion. Prior to co-founding Esperion, Dr. Newton was with Warner-Lambert/Parke-Davis (now Pfizer) from 1981-1998. As a Distinguished Scientist and Chairman of the Atherosclerosis Drug Discovery Team, he co-discovered and was the product champion of what is now the most prescribed cholesterol reducing drug in the world, atorvastatin (Lipitor®). Dr. Newton's research interests for the past thirty years have focused on the nutritional and pharmacological regulation of cholesterol and lipoprotein metabolism as they relate to atherosclerosis and vascular diseases. Dr. Newton is also an Adjunct Associate Professor in the Department of Pharmacology at the University of Michigan Medical School. He has co-authored nearly one hundred peer-reviewed articles and chapters during his research career. Dr. Newton completed a postdoctoral fellowship in the NIH sponsored Specialized Center of Research in Atherosclerosis at the University of California, San Diego. He has a Ph.D. in nutrition from the University of California Davis, a Masters of Science degree in nutritional biochemistry from the University of Connecticut and a Bachelor of Science in biology from Lafayette College.

“Dr. Newton’s addition to the Board brings a great deal of experience and credibility to our existing corporate structure. He has an immense amount of respect from both the international pharmaceutical and biotechnology communities. His exceptional track record will clearly add a very positive level of proven expertise in drug development, corporate finance and operational management to the Resverlogix Board,” said Donald McCaffrey, President and CEO of Resverlogix. “We are honored that he has chosen to join our team and we look forward to utilizing his substantial industry experience as we move forward in both our clinical trials for RVX-208 and our ongoing strategic analysis with UBS Securities.”

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company in the development of novel therapies for important global medical markets with significant unmet medical needs. The Company's primary focus is to conduct leading research, development and commercialization of novel therapeutics that enhance ApoA-I to address atherosclerosis, the main underlying cause of cardiovascular disease (CVD), The Company's secondary focus is TGF-Beta Shield™, a program that aims to address the

unmet medical needs of burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information, please visit our web site at www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

For further information please contact:

Theresa Kennedy
VP, Corporate Communications
Resverlogix Corp.
Phone: 604-538-7072
Fax: 403-256-8495
Email: Theresa@resverlogix.com

Kenneth Lebioda
SVP, Business & Market Development
Resverlogix Corp.
Phone: 403-254-9252
Fax: 403-256-8495
Email: Ken@resverlogix.com

Website: www.resverlogix.com